You are here

Marburg Virus Prophylactic Medical Countermeasure

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-18-P-0298
Agency Tracking Number: C18A-002-0016
Amount: $136,773.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: CBD18A-002
Solicitation Number: 2018.0
Timeline
Solicitation Year: 2018
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-20
Award End Date (Contract End Date): 2019-03-20
Small Business Information
45 Quail Ct 300, Walnut Creek, CA, 94596
DUNS: 080129637
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Reid Rubsamen
 (925) 708-8000
 rrubsamen@flowpharma.com
Business Contact
 Andrew Lloyd
Phone: (925) 238-2300
Email: atlloyd@gmail.com
Research Institution
 La Jolla Institute
 Reid Rubsamen MD
 9420 Athena Circle
La Jolla, CA, 92037
 (925) 708-8000
 Domestic nonprofit research organization
Abstract
Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by injection orinhalation. An open source computer model originally developed by Microsoft Research and enhanced by us with Artificial Intelligence deeplearning, allows us to select optimal class I epitope targets on viruses for CTL attack. We will use this computer model to select class I peptidesto Marburg proteins. We will then design complimentary class II peptides for the class I peptides using the TEPITOPE and ProPred algorithms.The La Jolla Institute for Allergy & Immunology will determine the MHC binding affinity of the selected class I and class II epitope candidatesfor selected Mamu and HLA specificities using purified MHC molecules and high affinity radiolabeled peptide ligands. High affinity cross-reactiveclass I and II peptides will be selected as vaccine candidates to protect Rhesus Macaques from a lethal challenge of Marburg virus with crossprotectivepeptides to protect humans.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government